NVS vs SLN
Novartis AG vs Silence Therapeutics plc — AI-powered side-by-side comparison
VS
SLN
Silence Therapeutics plc
48
Watch
| Metric | NVS | SLN |
|---|
| AI Score |
75
|
48
|
| Price |
$154.64
|
$14.69
|
| P/E Ratio |
23.55×
|
-6.72×
|
| ROE |
30.5%
|
-142.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
74.3%
|
68.6%
|
| Debt / Equity |
1.18×
|
0.00×
|
| Dividend Yield |
2.9%
|
0.0%
|
| RSI (14) |
57.7
|
74.4
|
| Beta |
0.462
|
1.351
|
| Expected Upside |
+2.4%
|
—
|
AI Committee View
Current Innellis committee reasoning for NVS versus SLN.
NVS leads by 27 points.
NVS scores 75/100 (Buy) versus SLN at 48/100 (Watch).
NVS Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
SLN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Growth Analyst remains cautious — revenue declining -99.3% yoy -- this is not a growth story right now. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -103.3% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 2.02 adds balance-sheet risk to the value case — Value
- Revenue declining -99.3% YoY -- this is not a growth story right now — Growth